4SC is a Munich-based cancer biopharmaceutical company. In this interview Jason Loveridge, CEO of 4SC, provides an overview of the company, its recent equity capital raise (€41m gross) and its updated and progressive development plan.
4SC has initiated (late 2016) its pivotal 150-patient study with its lead candidate resminostat (HDAC inhibitor) for cutaneous T-cell lymphoma (CTCL). Top-line data are expected by 2019. Alongside resminostat, 4SC intends to advance 4SC-202 into a first pivotal study (late 2018) and complete formal development of 4SC-208 with the aim of starting Phase I/II clinical testing (early 2019). Alongside its main goal of executing accelerated routes to market for its core cancer products, it also achieves value by out-licensing non-core assets. For example, a partnership with Link Health in China for its oncology Eg5 inhibitor, 4SC-205 and a worldwide license for 4SC’s preclinical inhibitors of the Kv1.3 ion channel.